Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PRESERVE: A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial Cancer

NCT07822373 is registered in ClinicalTrials.gov with University of Utah as lead sponsor.

NCT NCT07822373
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07822373 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PRESERVE: A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial Cancer
Lead sponsor
University of Utah
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
November 30, 2035
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

muscle-invasive bladder urothelial carcinoma